See the DrugPatentWatch profile for sapropterin

Sapropterin is a drug used to reduce the amino acid phenylalanine in the blood of individuals with a genetic disorder called phenylketonuria (PKU) [1]. According to a study published in the Orphanet Journal of Rare Diseases, sapropterin was used in a clinical trial for PKU patients aged between 1 and 45 years [2]. Another study in Molecular Genetics and Metabolism Reports examined the safety and efficacy of sapropterin in PKU patients aged 4 years and older [3].

Moreover, DrugPatentWatch.com lists sapropterin as a drug approved for PKU treatment, with clinical trials involving patients aged from infancy to adulthood [4]. The drug's usage in various age groups highlights the importance of sapropterin in managing PKU symptoms and maintaining phenylalanine levels within a safe range for individuals of different ages.

In summary, sapropterin has been used in clinical trials for PKU patients aged between 1 and 45 years [2], as well as those aged 4 years and older [3]. Additionally, DrugPatentWatch.com confirms sapropterin's use in PKU patients from infancy to adulthood [4].

Sources:
[1] "Sapropterin dihydrochloride." The National Center for Biotechnology Information, U.S. National Library of Medicine, <https://pubchem.ncbi.nlm.nih.gov/compound/Sapropterin-dihydrochloride>.
[2] van Spronsen, Frits J, et al. "Sapropterin dihydrochloride in phenylketonuria: a randomized, double-blind, placebo-controlled study." Orphanet Journal of Rare Diseases, vol. 3, no. 1, 2008, p. 33., doi:10.1186/1750-1172-3-33.
[3] Burton, B K, et al. "Efficacy and safety of high-dose sapropterin dihydrochloride in phenylketonuria." Molecular Genetics and Metabolism Reports, vol. 19, 2019, p. 100544., doi:10.1016/j.ymgmr.2019.100544.
[4] "Sapropterin Dihydrochloride (KUVAN®)." DrugPatentWatch.com, <https://www.drugpatentwatch.com/drugs/sapropterin-dihydrochloride>.